

Other focused conferences during WorldPharma2010

- 1: Clinical pharmacology in emerging and developing countries
- 2: Transmembrane transport: perspectives for disease and drug discovery
- 3: Ion channels in analgesia and anaesthesia
- 4: Pharmacoepidemiology, current controversies and opportunities
- 6: The heart gone wrong; stabilization of cardiac function
- 7: Simulation and data modelling in drug development. Better drugs faster?
- 8: Developments in the treatment of sexual dysfunction and diseases of the lower urinary tract
- 9: Inflammation and immunopharmacology: new tools for old diseases
- 10: Drugs for half the world: paediatric clinical pharmacology
- 11: G protein-coupled 7TM receptors:
from molecular to physiological function
- 12: Ion channelopathies:
new windows on complex disease and therapy
- 13: Maximising benefits and minimizing harms from drugs
- 14: Addiction and doping:
neurobiological and clinical basis of emerging treatments
- 15: Endothelium in health and disease
- 16: Natural products: past and future?
- 17: New approaches and targets in psychiatry
- 18: Nuclear receptor targets for treatment of diseases

Danish Society for 
Pharmacology



BCPT
Basic & Clinical Pharmacology & Toxicology



Printed in Denmark

Please find further details on www.WorldPharma2010.org



WorldPharma2010

16th World Congress on Basic and Clinical Pharmacology.
July 17-23, 2010, Copenhagen, Denmark

WorldPharma2010 will include a
2-day focused conference on

**Translational science in
the metabolic syndrome:
basic and clinical
pharmacology**

19-20 July 2010

Abstract deadline 15 January 2010
Early bird registration deadline 15 March 2010

Invitation

July 17-23 2010 is the time for a major event for pharmacology, the science of how drugs affect the living organism. Basic and clinical pharmacology, kept separate for too long, have come together again to encompass the whole process of drug development from molecular biology to clinical practice. This remarriage is to be celebrated in Copenhagen; the world's basic and clinical pharmacologists and all those dealing with the development and use of drugs will meet to discuss how we can work together to meet the need for safe and effective medicines at affordable prices.

WorldPharma2010 is organised by the Danish Society for Pharmacology jointly with the British Pharmacological Society under the auspices of the International Union of Basic and Clinical Pharmacology, IUPHAR.

In the scientific programme, there will be plenary lectures, poster sessions, sponsored symposia, workshops, satellite meetings and focused conferences. Each of the 18 focused conferences contains 4 or 5 half-day sessions all belonging to the same theme. Overleaf is the detailed programme for the focused conference entitled:

"Translational science in the metabolic syndrome: basic and clinical pharmacology"

The titles of the other focused conferences are listed on the back of the folder.

In each session there will be free communications as well. We promise you a scientifically excellent programme as well as the opportunity to savour the atmosphere of Copenhagen.



Kim Brøsen
President



Michael Mulvany
Secretary General

Congress secretariat

ICS A/S Copenhagen
Strandvejen 169-171 - P.O. Box 41 - DK-2900 Hellerup, Copenhagen - Denmark
Email: WorldPharma2010@ics.dk - Phone: +45 7023 7823 - Fax: +45 7023 7888
www.worldpharma2010.org



Translational science in the metabolic syndrome: basic and clinical pharmacology

Sponsored by an unrestricted grant from Novo Nordisk A/S

Focused conference leaders: L. Groop, H. Beck-Nielsen & J. E. Henriksen

Session 1

New molecular targets in metabolic syndrome

Chairpersons:
J. Rungby & A. Krook

- Adipose tissue, reducing inflammation as a means of targeting the metabolic syndrome
B. Richelsen, Denmark
- The muscle as a target for treatment of the metabolic syndrome
A. Krook, Sweden
- Sodium glucose co-transporter 2 inhibitors in the treatment of hyperglycaemia
J. Wilding, UK
- Solute carrier family 30 proteins as targets for beta-cell stimulation
F. Chimienti, France

Session 2

Pharmacotherapy in type 2 Diabetes Mellitus complicated with cardiovascular disease

Chairpersons:
H. E. Bøtker & P. Iozzo

- Insulin resistance: marker or mediator of increased cardiovascular risk?
H. Taegtmeyer, USA
- Pathophysiology and treatment of heart failure in patients with type 2 Diabetes Mellitus
P. G. Camici, UK
- Antithrombotic treatment in patients with type 2 DM
S. D. Kristensen, Denmark
- Polypharmacy in type 2 DM
J. T. Backmann, Finland

Session 3

Normalizing blood glucose in metabolic syndrome I: GLP-1 analogues and DPP IV inhibitors

Chairpersons:
J. Juul-Holst & M. Nauck

- The GLP-1 receptor as a target for treatment of diabetes
L. B. Knudsen, Denmark
- Incretin mimetics 2010: the safety experience
D. Kendall, USA
- GLP-1 secretion as a prerequisite for the antidiabetic activity of DPP-4 inhibitors: can it be modified?
F. Gribble, UK
- Incretin-based medication and cardiovascular disease
B. Gallwitz, Germany

Session 4

Normalizing blood glucose in metabolic syndrome II: glitazones and metformin

Chairpersons:
P. Home & J. E. Henriksen

- The role of metformin and glitazones in the regulation on hepatic glucose metabolism
M. Roden, Germany
- Rosiglitazone: lessons from the RECORD study
P. Home, UK
- Metformin: Lessons from UKPDS
A. Adler, UK
- Translational science in metabolic syndrome – future directions
H. Beck-Nielsen, Denmark